Insight

Megan E. Tesch: Estrogen levels in young patients on OFS treatment for breast cancer

Photo taken from Megan E. Tesch/X

Aug 3, 2024, 06:00

Megan E. Tesch: Estrogen levels in young patients on OFS treatment for breast cancer

Megan E. Tesch, Medical oncologist at Dana-Farber Cancer Institute, shared on X:

“What are the clinical implications of incomplete ovarian function suppression? In this study we evaluate estrogen levels in young patients on OFS treatment for breast cancer with ultrasensitive assays and correlate with outcomes.

‘Estrogen levels in young women with hormone receptor-positive breast cancer on ovarian function suppression therapy‘

Authors: Megan E. Tesch, Yue Zheng, Shoshana M. Rosenberg, Philip D. Poorvu, Kathryn J. Ruddy, Rulla Tamimi, Lidia Schapira, Jeffrey Peppercorn, Virginia Borges, Steven E. Come, Craig Snow, Shalender Bhasin Ann H. Partridge.⁦”

Source: Megan E. Tesch/X

Breast Cancer cancer Craig Snow Jeffrey Peppercorn Kathryn J. Ruddy Lidia Schapira Megan E. Tesch OncoDaily Oncology Philip D. Poorvu Rulla Tamimi Shalender Bhasin Ann H. Partridge Shoshana M. Rosenberg Steven E. Come Virginia Borges Yue Zheng

Karen Knudsen has been appointed as the CEO of the Parker Institute for Cancer Immunotherapy

Highlights from ELCC 2025

FDA Approved Pluvicto (177Lu-PSMA-617) for Metastatic Castration-Resistant Prostate Cancer

Meet the New AACR Board of Directores for 2025-2028 Term

Do Artificial Sweeteners Cause Cancer? Myths and Facts